{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:06:23Z","timestamp":1761919583701},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Dihydropyridine calcium channel blockers (CCBs) are more effective in reducing carotid intima-media thickness (IMT) than other classes of antihypertensive drugs due to their vascular effects. However, the mechanism remains to be elucidated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Findings<\/jats:title>\n            <jats:p>Ox-LDL induced HUVSMCs proliferation in a time- and dose-dependent manner. When pretreated with three CCBs before 50\u2009\u03bcg\/ml ox-LDL stimulation, 30\u2009\u03bcM lacidipine and 3\u2009\u03bcM amlodipine exhibited 27% and 18% decrease of pro-proliferative effect induced by ox-LDL, whereas (<jats:italic>S<\/jats:italic>-)-amlodipine did not have any anti-proliferative effect. 30\u2009\u03bcM lacidipine inhibited about two-thirds of the ox-LDL induced ROS production in HUVSMCs, whereas amlodipine and (<jats:italic>S<\/jats:italic>-)-amlodipine did not have influence on ROS production. The MAPKs pathway inhibitors inhibited the ox-LDL induced proliferation of HUVSMCs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Our study has demonstrated that lipophilic CCBs, such as lacidipine may inhibit ox-LDL induced proliferation and oxidative stress of VSMCs, and that the ROS-MAPKs pathway might be involved in the mechanism.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1756-0500-5-168","type":"journal-article","created":{"date-parts":[[2012,3,28]],"date-time":"2012-03-28T14:15:02Z","timestamp":1332944102000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Effects of dihydropyridine calcium channel blockers on oxidized low-density lipoprotein induced proliferation and oxidative stress of vascular smooth muscle cells"],"prefix":"10.1186","volume":"5","author":[{"given":"Jun","family":"Zou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Qi","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Guang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,3,28]]},"reference":[{"key":"1507_CR1","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1161\/01.STR.0000227223.90239.13","volume":"37","author":"JG Wang","year":"2006","unstructured":"Wang JG, Staessen JA, Li Y, Van Bortel LM, Nawrot T, Fagard R, Messerli FH, Safar M: Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials. Stroke. 2006, 37: 1933-1940. 10.1161\/01.STR.0000227223.90239.13.","journal-title":"Stroke"},{"key":"1507_CR2","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1161\/HYPERTENSIONAHA.107.089763","volume":"50","author":"JG Wang","year":"2007","unstructured":"Wang JG, Li Y, Franklin SS, Safar M: Prevention of stroke and myocardial infarction by amlodipine and Angiotensin receptor blockers: a quantitative overview. Hypertension. 2007, 50: 181-188. 10.1161\/HYPERTENSIONAHA.107.089763.","journal-title":"Hypertension"},{"key":"1507_CR3","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1038\/sj.bjp.0703976","volume":"132","author":"CM Yang","year":"2001","unstructured":"Yang CM, Chien CS, Hsiao LD, Pan SL, Wang CC, Chiu CT, Lin CC: Mitogenic effect of oxidized low-density lipoprotein on vascular smooth muscle cells mediated by activation of Ras\/Raf\/MEK\/MAPK pathway. Br J Pharmacol. 2001, 132: 1531-1541. 10.1038\/sj.bjp.0703976.","journal-title":"Br J Pharmacol"},{"key":"1507_CR4","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.yjmcc.2008.10.009","volume":"46","author":"MN Chahine","year":"2009","unstructured":"Chahine MN, Blackwood DP, Dibrov E, Richard MN, Pierce GN: Oxidized LDL affects smooth muscle cell growth through MAPK-mediated actions on nuclear protein import. J Mol Cell Cardiol. 2009, 46: 431-441. 10.1016\/j.yjmcc.2008.10.009.","journal-title":"J Mol Cell Cardiol"},{"key":"1507_CR5","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S0955-0674(98)80147-6","volume":"10","author":"T Finkel","year":"1998","unstructured":"Finkel T: Oxygen radicals and signaling. Curr Opin Cell Biol. 1998, 10: 248-253. 10.1016\/S0955-0674(98)80147-6.","journal-title":"Curr Opin Cell Biol"},{"key":"1507_CR6","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1161\/01.CIR.102.13.1503","volume":"102","author":"B Pitt","year":"2000","unstructured":"Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME, Riley W: Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation. 2000, 102: 1503-1510. 10.1161\/01.CIR.102.13.1503.","journal-title":"Circulation"},{"key":"1507_CR7","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1161\/01.CIR.0000039288.86470.DD","volume":"106","author":"A Zanchetti","year":"2002","unstructured":"Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palu C, Hansson L, Magnani B, Rahn KH, Reid JL, Rodicio J, Safar M, Eckes L, Rizzini P: Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation. 2002, 106: 2422-2427. 10.1161\/01.CIR.0000039288.86470.DD.","journal-title":"Circulation"},{"key":"1507_CR8","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1291\/hypres.31.1147","volume":"31","author":"S Ogawa","year":"2008","unstructured":"Ogawa S, Mori T, Nako K, Ito S: Combination therapy with renin-angiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy. Hypertens Res. 2008, 31: 1147-1155. 10.1291\/hypres.31.1147.","journal-title":"Hypertens Res"},{"key":"1507_CR9","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.2165\/00003495-200363210-00008","volume":"63","author":"PL McCormack","year":"2003","unstructured":"McCormack PL, Wagstaff AJ: Lacidipine: a review of its use in the management of hypertension. Drugs. 2003, 63: 2327-2356. 10.2165\/00003495-200363210-00008.","journal-title":"Drugs"},{"key":"1507_CR10","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/00005344-200202000-00007","volume":"39","author":"XP Zhang","year":"2002","unstructured":"Zhang XP, Loke KE, Mital S, Chahwala S, Hintze TH: Paradoxical release of nitric oxide by an L-type calcium channel antagonist, the R+enantiomer of amlodipine. J Cardiovasc Pharmacol. 2002, 39: 208-214. 10.1097\/00005344-200202000-00007.","journal-title":"J Cardiovasc Pharmacol"},{"key":"1507_CR11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1159\/000074241","volume":"70","author":"R Berkels","year":"2004","unstructured":"Berkels R, Taubert D, Bartels H, Breitenbach T, Klaus W, Roesen R: Amlodipine increases endothelial nitric oxide by dual mechanisms. Pharmacology. 2004, 70: 39-45. 10.1159\/000074241.","journal-title":"Pharmacology"},{"key":"1507_CR12","doi-asserted-by":"publisher","first-page":"D619","DOI":"10.2741\/sanz","volume":"5","author":"SM Sanz-Gonzalez","year":"2000","unstructured":"Sanz-Gonzalez SM, Poch E, Perez-Roger I, Diez-Juan A, Ivorra C, Andres V: Control of vascular smooth muscle cell growth by cyclin-dependent kinase inhibitory proteins and its implication in cardiovascular disease. Front Biosci. 2000, 5: D619-D628. 10.2741\/sanz.","journal-title":"Front Biosci"},{"key":"1507_CR13","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1161\/ATVBAHA.107.159327","volume":"28","author":"AC Doran","year":"2008","unstructured":"Doran AC, Meller N, McNamara CA: Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler Thromb Vasc Biol. 2008, 28: 812-819. 10.1161\/ATVBAHA.107.159327.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1507_CR14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1161\/hh1301.093615","volume":"89","author":"B Su","year":"2001","unstructured":"Su B, Mitra S, Gregg H, Flavahan S, Chotani MA, Clark KR, Goldschmidt-Clermont PJ, Flavahan NA: Redox regulation of vascular smooth muscle cell differentiation. Circ Res. 2001, 89: 39-46. 10.1161\/hh1301.093615.","journal-title":"Circ Res"},{"key":"1507_CR15","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1097\/00004872-199715120-00065","volume":"15","author":"L Cominacini","year":"1997","unstructured":"Cominacini L, Garbin U, Fratta PA, Paulon T, Davoli A, Campagnola M, Marchi E, Pastorino AM, Gaviraghi G, Lo CV: Lacidipine inhibits the activation of the transcription factor NF-kappaB and the expression of adhesion molecules induced by pro-oxidant signals on endothelial cells. J Hypertens. 1997, 15: 1633-1640. 10.1097\/00004872-199715120-00065.","journal-title":"J Hypertens"},{"key":"1507_CR16","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1097\/00004872-199816121-00010","volume":"16","author":"L Cominacini","year":"1998","unstructured":"Cominacini L, Garbin U, Pasini AF, Davoli A, Campagnola M, Pastorino AM, Gaviraghi G, Lo CV: Oxidized low-density lipoprotein increases the production of intracellular reactive oxygen species in endothelial cells: inhibitory effect of lacidipine. J Hypertens. 1998, 16: 1913-1919. 10.1097\/00004872-199816121-00010.","journal-title":"J Hypertens"},{"key":"1507_CR17","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1096\/fj.04-1662com","volume":"18","author":"R Ziesche","year":"2004","unstructured":"Ziesche R, Petkov V, Lambers C, Erne P, Block LH: The calcium channel blocker amlodipine exerts its anti-proliferative action via p21(Waf1\/Cip1) gene activation. FASEB J. 2004, 18: 1516-1523. 10.1096\/fj.04-1662com.","journal-title":"FASEB J"},{"key":"1507_CR18","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.bbrc.2008.02.075","volume":"369","author":"T Ohba","year":"2008","unstructured":"Ohba T, Watanabe H, Murakami M, Radovanovic M, Iino K, Ishida M, Tosa S, Ono K, Ito H: Amlodipine inhibits cell proliferation via PKD1-related pathway. Biochem Biophys Res Commun. 2008, 369: 376-381. 10.1016\/j.bbrc.2008.02.075.","journal-title":"Biochem Biophys Res Commun"},{"key":"1507_CR19","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1161\/01.ATV.0000097770.66965.2A","volume":"23","author":"RP Mason","year":"2003","unstructured":"Mason RP, Marche P, Hintze TH: Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine. Arterioscler Thromb Vasc Biol. 2003, 23: 2155-2163. 10.1161\/01.ATV.0000097770.66965.2A.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1507_CR20","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1006\/jmcc.1998.0867","volume":"31","author":"RP Mason","year":"1999","unstructured":"Mason RP, Walter MF, Trumbore MW, Olmstead EG, Mason PE: Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine. J Mol Cell Cardiol. 1999, 31: 275-281. 10.1006\/jmcc.1998.0867.","journal-title":"J Mol Cell Cardiol"},{"key":"1507_CR21","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1098\/rstb.2005.1774","volume":"360","author":"T Godfraind","year":"2005","unstructured":"Godfraind T: Antioxidant effects and the therapeutic mode of action of calcium channel blockers in hypertension and atherosclerosis. Philos Trans R Soc Lond, B, Biol Sci. 2005, 360: 2259-2272. 10.1098\/rstb.2005.1774.","journal-title":"Philos Trans R Soc Lond, B, Biol Sci"},{"key":"1507_CR22","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/j.0959-9673.2004.00375.x","volume":"85","author":"P Cristofori","year":"2004","unstructured":"Cristofori P, Crivellente F, Campagnola M, Pasini AF, Garbin U, Rigoni A, Tosetti M, Turton J, Faustinelli I, Cominacini L: Reduced progression of atherosclerosis in apolipoprotein E-deficient mice treated with lacidipine is associated with a decreased susceptibility of low-density lipoprotein to oxidation. Int J Exp Pathol. 2004, 85: 105-114. 10.1111\/j.0959-9673.2004.00375.x.","journal-title":"Int J Exp Pathol"},{"key":"1507_CR23","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s11010-009-0080-y","volume":"328","author":"MS Keles","year":"2009","unstructured":"Keles MS, Bayir Y, Suleyman H, Halici Z: Investigation of effects of Lacidipine, Ramipril and Valsartan on DNA damage and oxidative stress occurred in acute and chronic periods following isoproterenol-induced myocardial infarct in rats. Mol Cell Biochem. 2009, 328: 109-117. 10.1007\/s11010-009-0080-y.","journal-title":"Mol Cell Biochem"},{"key":"1507_CR24","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1161\/CIRCULATIONAHA.108.773119","volume":"120","author":"A Zanchetti","year":"2009","unstructured":"Zanchetti A, Hennig M, Hollweck R, Bond G, Tang R, Cuspidi C, Parati G, Facchetti R, Mancia G: Baseline values but not treatment-induced changes in carotid intima-media thickness predict incident cardiovascular events in treated hypertensive patients: findings in the European Lacidipine Study on Atherosclerosis (ELSA). Circulation. 2009, 120: 1084-1090. 10.1161\/CIRCULATIONAHA.108.773119.","journal-title":"Circulation"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-0500-5-168.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T19:09:15Z","timestamp":1630523355000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/1756-0500-5-168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,28]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["1507"],"URL":"https:\/\/doi.org\/10.1186\/1756-0500-5-168","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,28]]},"assertion":[{"value":"28 February 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"168"}}